相似文献
1
Angiogenesis inhibition in prostate cancer: current uses and future promises.
J Oncol. 2010;2010:361836. doi: 10.1155/2010/361836. Epub 2010 Feb 11.
2
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22.
3
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. doi: 10.2174/1568011033353452.
4
Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
J Cell Physiol. 2019 May;234(5):5655-5663. doi: 10.1002/jcp.27414. Epub 2018 Dec 4.
5
Angiogenesis inhibitors in the treatment of prostate cancer.
Expert Opin Pharmacother. 2010 Feb;11(2):233-47. doi: 10.1517/14656560903451716.
6
Antiangiogenic agents in cancer therapy.
Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):17-25.
7
Angiogenesis and prostate cancer: important laboratory and clinical findings.
Curr Oncol Rep. 2005 May;7(3):215-9. doi: 10.1007/s11912-005-0076-z.
8
Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
BMC Syst Biol. 2015 Sep 4;9:55. doi: 10.1186/s12918-015-0201-z.
9
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Cancer Res. 2004 Sep 15;64(18):6626-34. doi: 10.1158/0008-5472.CAN-04-0540.
10
Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9.
引用本文的文献
1
Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.
Int J Mol Sci. 2021 Sep 14;22(18):9926. doi: 10.3390/ijms22189926.
2
Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.
Rev Physiol Biochem Pharmacol. 2021;181:39-56. doi: 10.1007/112_2020_22.
3
Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth.
Sci Rep. 2017 Nov 8;7(1):15060. doi: 10.1038/s41598-017-12408-1.
4
Adrenergic nerves activate an angio-metabolic switch in prostate cancer.
Science. 2017 Oct 20;358(6361):321-326. doi: 10.1126/science.aah5072.
5
CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.
Oncotarget. 2017 Apr 4;8(14):22406-22413. doi: 10.18632/oncotarget.9899.
6
Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer.
Cent European J Urol. 2016;69(1):63-71. doi: 10.5173/ceju.2016.726. Epub 2016 Jan 25.
7
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.
BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8.
8
Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.
BMC Cancer. 2014 Jun 13;14:433. doi: 10.1186/1471-2407-14-433.
9
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.
BMC Health Serv Res. 2014 Jun 13;14:252. doi: 10.1186/1472-6963-14-252.
10
Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.
Int J Mol Sci. 2013 Jun 7;14(6):12249-72. doi: 10.3390/ijms140612249.
本文引用的文献
1
Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino.
Ann Oncol. 2008 Oct;19(10):1813-1814. doi: 10.1093/annonc/mdn549. Epub 2019 Dec 3.
2
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.
J Clin Oncol. 2009 Nov 20;27(33):5627-33. doi: 10.1200/JCO.2008.20.8876. Epub 2009 Oct 26.
3
The role of vascular endothelial growth factor genetic variability in cancer.
Clin Cancer Res. 2009 Sep 1;15(17):5297-302. doi: 10.1158/1078-0432.CCR-08-2576. Epub 2009 Aug 25.
4
Cancer statistics, 2009.
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
5
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
J Clin Pharmacol. 2009 Jun;49(6):650-60. doi: 10.1177/0091270009335001.
6
Phase II study of sunitinib in men with advanced prostate cancer.
Ann Oncol. 2009 May;20(5):913-20. doi: 10.1093/annonc/mdp111.
7
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
Expert Opin Biol Ther. 2009 Feb;9(2):263-71. doi: 10.1517/14712590802666397.
8
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU Int. 2009 Jun;103(12):1636-40. doi: 10.1111/j.1464-410X.2008.08327.x. Epub 2009 Jan 9.
9
Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study.
Urol Oncol. 2010 Jan-Feb;28(1):21-7. doi: 10.1016/j.urolonc.2008.06.003. Epub 2008 Sep 12.
10
About sorafenib in castration-resistant prostate cancer.
Ann Oncol. 2008 Oct;19(10):1812-3; author reply 1813-1814. doi: 10.1093/annonc/mdn546. Epub 2008 Aug 9.
Zotero 插件